{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:22:59Z","timestamp":1786123379772,"version":"build-2736575974"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1213\/ane.0b013e31825d3749","type":"journal-article","created":{"date-parts":[[2012,6,20]],"date-time":"2012-06-20T15:40:03Z","timestamp":1340206803000},"page":"925-928","source":"Crossref","is-referenced-by-count":3,"title":["Ondansetron-Induced Muscular Contractures in Malignant Hyperthermia-Susceptible Individuals"],"prefix":"10.1213","volume":"115","author":[{"given":"Stephan","family":"Johannsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Roewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-30-20210902","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1517\/14656566.8.18.3217","article-title":"Recent advances, trends and economic considerations in the risk assessment, prevention and treatment of postoperative nausea and vomiting.","volume":"18","author":"Kranke","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"R2-30-20210902","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1542\/peds.2009-2795","article-title":"Administration of ondansetron is associated with lethal outcome.","volume":"125","author":"Gener","year":"2010","journal-title":"Pediatrics"},{"key":"R3-30-20210902","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1055\/s-0029-1242125","article-title":"Malignant hyperthermiadiagnostics, treatment and anaesthetic management.","volume":"44","author":"Schuster","year":"2009","journal-title":"Anasthesiol Intensivmed Notfallmed Schmerzther"},{"key":"R4-30-20210902","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/bja\/aer132","article-title":"Malignant hyperthermia: pharmacology of triggering.","volume":"107","author":"Hopkins","year":"2011","journal-title":"Br J Anaesth"},{"key":"R5-30-20210902","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/bja\/56.11.1267","article-title":"A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility.","volume":"56","year":"1984","journal-title":"Br J Anaesth"},{"key":"R6-30-20210902","first-page":"511","article-title":"Standardization of the caffeine halothane muscle contracture test.","volume":"69","year":"1989","journal-title":"Anesth Analg"},{"key":"R8-30-20210902","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1097\/ALN.0b013e3182320068","article-title":"Identical de novo mutation in the type 1 ryanodine receptor gene associated with fatal, stress-induced malignant hyperthermia in two unrelated families.","volume":"115","author":"Groom","year":"2011","journal-title":"Anesthesiology"},{"key":"R9-30-20210902","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/00000542-200109000-00009","article-title":"North American malignant hyperthermia population: screening of the ryanodine receptor gene and identification of novel mutations.","volume":"95","author":"Sambuughin","year":"2001","journal-title":"Anesthesiology"},{"key":"R10-30-20210902","first-page":"409","article-title":"Mild clinical and histopathological features in patients who carry the frequent and causative malignant hyperthermia RyR1 mutation p.Thr2206Met.","volume":"28","author":"Rueffert","year":"2009","journal-title":"Clin Neuropathol"},{"key":"R12-30-20210902","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1097\/00000542-199606000-00002","article-title":"Effects of the serotonin2 receptor agonist DOI on skeletal muscle specimens from malignant hyperthermia-susceptible patients.","volume":"84","author":"Wappler","year":"1996","journal-title":"Anesthesiology"},{"key":"R13-30-20210902","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/BF00171727","article-title":"Pharmacodynamic effects of serotonin (5-HT) receptor ligands in pigs: stimulation of 5-HT2 receptors induces malignant hyperthermia.","volume":"341","author":"Loscher","year":"1990","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"R15-30-20210902","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0952-8180(97)00008-1","article-title":"Ritanserin attenuates the in vitro effects of the 5-HT2 receptor agonist DOI on skeletal muscles from malignant hyperthermia-susceptible patients.","volume":"9","author":"Wappler","year":"1997","journal-title":"J Clin Anesth"},{"key":"R16-30-20210902","first-page":"640","article-title":"Inhibition of serotonin of amino acid release and protein degradation in skeletal muscle.","volume":"13","author":"Garber","year":"1977","journal-title":"Mol Pharmacol"},{"key":"R17-30-20210902","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/00000542-199207000-00023","article-title":"Postoperative nausea and vomiting. Its etiology, treatment, and prevention.","volume":"77","author":"Watcha","year":"1992","journal-title":"Anesthesiology"},{"key":"R18-30-20210902","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1213\/01.ANE.0000160531.65953.77","article-title":"Antiemetics of the 5-hydroxytryptamine 3A antagonist class inhibit muscle nicotinic acetylcholine receptors.","volume":"101","author":"Paul","year":"2005","journal-title":"Anesth Analg"},{"key":"R19-30-20210902","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/00007611-199305000-00002","article-title":"Ondansetron: a novel antiemetic agent.","volume":"86","author":"Figg","year":"1993","journal-title":"South Med J"},{"key":"R20-30-20210902","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/00003643-200307000-00003","article-title":"Multicentre evaluation of in vitro contracture testing with bolus administration of 4-chloro-m-cresol for diagnosis of malignant hyperthermia susceptibility.","volume":"20","author":"Wappler","year":"2003","journal-title":"Eur J Anaesthesiol"},{"key":"R21-30-20210902","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1034\/j.1399-6576.2000.440321.x","article-title":"The impact of 4-chloro-m-cresol in heparin formulas on malignant hyperthermia: in vitro and in vivo.","volume":"44","author":"Anetseder","year":"2000","journal-title":"Acta Anaesthesiol Scand"}],"container-title":["Anesthesia & Analgesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1213\/ANE.0b013e31825d3749","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:18:50Z","timestamp":1786112330000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000539-201210000-00030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1213\/ane.0b013e31825d3749","relation":{},"ISSN":["0003-2999"],"issn-type":[{"value":"0003-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}